VASOPRESSIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vasopressin, and when can generic versions of Vasopressin launch?
Vasopressin is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Cipla, Eagle Pharms, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, and Baxter Hlthcare Corp. and is included in nine NDAs.
The generic ingredient in VASOPRESSIN is vasopressin. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vasopressin
A generic version of VASOPRESSIN was approved as vasopressin by AM REGENT on August 3rd, 2020.
Summary for VASOPRESSIN
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 9 |
| Clinical Trials: | 245 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VASOPRESSIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VASOPRESSIN |
| What excipients (inactive ingredients) are in VASOPRESSIN? | VASOPRESSIN excipients list |
| DailyMed Link: | VASOPRESSIN at DailyMed |
Recent Clinical Trials for VASOPRESSIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alberta | Phase 1 |
| Qianfoshan Hospital | N/A |
| Erzincan Military Hospital | Phase 4 |
Pharmacology for VASOPRESSIN
| Physiological Effect | Decreased Diuresis Vasoconstriction |
Paragraph IV (Patent) Challenges for VASOPRESSIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VASOSTRICT | Injection | vasopressin | 20 units/100 mL | 204485 | 1 | 2022-12-20 |
| VASOSTRICT | Injection | vasopressin | 40 units/100 mL and 60 units/100 mL | 204485 | 1 | 2022-02-28 |
| VASOSTRICT | Injection | vasopressin | 200 units/10 mL | 204485 | 1 | 2018-06-29 |
| VASOSTRICT | Injection | vasopressin | 20 units/mL, 1 mL | 204485 | 1 | 2018-03-23 |
US Patents and Regulatory Information for VASOPRESSIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 212593-001 | Aug 3, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eugia Pharma | VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 214314-001 | Aug 15, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Amphastar Pharms Inc | VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 211857-001 | Jul 18, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Fresenius Kabi Usa | VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 213206-001 | May 26, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Am Regent | VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 212593-002 | Jun 9, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
